MADISON, N.J.--(BUSINESS WIRE)--ZoetisTM (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., today announced the closing of its previously announced initial public offering. The offering of 99,015,000 shares of its Class A common stock included 12,915,000 shares of Class A common stock that were sold pursuant to the underwriters’ option to purchase additional shares, which was exercised in full prior to the closing.
Zoetis did not receive any of the proceeds of the offering. Following the completion of the initial public offering, Pfizer owns 100% of the outstanding Class B common stock of Zoetis and retains an approximately 80% ownership of Zoetis.
J.P. Morgan, BofA Merrill Lynch and Morgan Stanley served as joint lead book-running managers for the offering. Barclays, Citigroup, Credit Suisse, Deutsche Bank Securities, Goldman, Sachs & Co., Guggenheim Securities and Jefferies served as book-running managers for the offering. BNP PARIBAS, HSBC, Loop Capital Markets, RBC Capital Markets, The Williams Capital Group, L.P. and UBS Investment Bank served as senior co-managers for the offering. Lebenthal Capital Markets, Piper Jaffray and Ramirez & Co., Inc. served as co-managers for the offering.
The offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; BofA Merrill Lynch, Attention: Prospectus Department, 222 Broadway, New York, NY 10038, email: email@example.com; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, email: firstname.lastname@example.org, telephone: (866) 718-1649.
A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction.
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both farm and companion animals. The company generated annual revenue of $4.2 billion in fiscal 2011. Zoetis has more than 9,500 employees and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries.
DISCLOSURE NOTICE: This news release contains forward-looking statements, which reflect Zoetis’ current views with respect to business plans or prospects, future operating or financial performance, and other future events. These statements are not guarantees of future performance. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of these risks, uncertainties and other factors can be found in Zoetis’ Registration Statement on Form S-1 (File No. 333-183254), as amended, filed with the Securities and Exchange Commission. This filing and subsequent filings are available online at www.sec.gov or on request from Zoetis.